Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy

J Urol. 2004 Aug;172(2):529-32. doi: 10.1097/01.ju.0000130508.61020.66.

Abstract

Purpose: We determined the risk factors for osteoporosis and spinal fractures in men with prostate cancer receiving androgen deprivation therapy.

Materials and methods: We performed a retrospective analysis of 87 consecutive men with prostate cancer receiving androgen deprivation therapy referred for evaluation of osteoporosis. Data were comprised of lateral thoracolumbar radiographs, bone densitometry, serum biochemistry and a detailed assessment of osteoporotic risk factors. Multivariate regression analysis was used to determine the major risk factors for osteoporosis and spinal fractures.

Results: There were 38 (44%) men who were 74.5 years old with radiographic evidence of spinal fractures. They had an initial mean prostate specific antigen of 52.8 ng/ml and had received androgen deprivation therapy for a mean of 39.6 months (95% confidence interval 28.7 to 50.4). Mean spinal (quantitative computerized tomography t-score -4.2) and femoral neck bone mineral densities (dual energy x-ray absorptiometry t-score -2.1) were significantly lower than in men without spinal fractures (p < 0.001 for all measurements). In the regression analysis the duration of androgen deprivation therapy (p = 0.002), serum 25-hydroxyvitamin D levels (p = 0.003) and a history of alcohol excess (defined as more than 4 standard drinks daily, p = 0.04) were the main determinants of spinal fractures.

Conclusions: Prolonged androgen deprivation therapy, low serum 25-hydroxyvitamin D levels and a history of alcohol excess are important risk factors for osteoporosis and spinal fractures in men with prostate cancer.

MeSH terms

  • Aged
  • Alcohol Drinking
  • Androgen Antagonists / therapeutic use
  • Anilides / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Comorbidity
  • Flutamide / therapeutic use
  • Goserelin / therapeutic use
  • Humans
  • Male
  • Multivariate Analysis
  • Nitriles
  • Osteoporosis / epidemiology*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / epidemiology*
  • Retrospective Studies
  • Risk Factors
  • Spinal Fractures / epidemiology*
  • Time Factors
  • Tosyl Compounds
  • Vitamin D / analogs & derivatives*
  • Vitamin D / therapeutic use

Substances

  • Androgen Antagonists
  • Anilides
  • Antineoplastic Agents, Hormonal
  • Nitriles
  • Tosyl Compounds
  • Goserelin
  • Vitamin D
  • Flutamide
  • bicalutamide
  • 25-hydroxyvitamin D